Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pain drugs with safety questions will get advisory committee review

Executive Summary

FDA will hold a joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Jan. 30 to weigh the available safety and efficacy data for all propoxyphene-containing products (including hydrochloric acid, napsylate salts and combination drugs) and decide whether any regulatory action is appropriate. In June 2008, Public Citizen Litigation Group sued FDA for failing to withdraw products containing the painkiller propoxyphene, including AAIPharma's Darvocet (1"The Pink Sheet," July 7, 2008, p. 26)

You may also be interested in...



Public Citizen Litigation Group: Industry’s Relentless Adversary

Public Citizen Litigation Group has had plenty to cheer about this year. It argued four cases before the U.S. Supreme Court, winning three of them. Its one loss was particularly disappointing, though

Health And Wellness Trademark Review 2 March, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

In Order Shutting Down New York Supplement Firm, Federal Judge Also Criticizes FDA’s Calculations

Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel